

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Growth 2022-2028

<https://marketpublishers.com/r/GD91A7A7453EEN.html>

Date: February 2022

Pages: 96

Price: US\$ 3,660.00 (Single User License)

ID: GD91A7A7453EEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

As the global economy mends, the 2021 growth of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) will have significant change from previous year. According to our (LP Information) latest study, the global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.

The United States Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) market is expected at value of US\$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) market, reaching US\$ million by the year 2028. As for the Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) landscape, Germany is projected to reach US\$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.

Global main Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) players cover Boya-Bio, Beijing Tiantan Biological Products, Hualan Bio, and Guangdong Shuagnlin Bio-pharmacy, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth

opportunities of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6

1g/20ml

1.25g/25ml

2.5g/50ml

5g/100ml

10g/200ml

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.

Hospital

Clinic

Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include

Boya-Bio

Beijing Tiantan Biological Products

Hualan Bio

Guangdong Shuagnlin Bio-pharmacy

Weiguang Biological

Sinopharm

Shanghai RAAS

CTBB

Nanyue Biopharming

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Country/Region, 2017, 2022 & 2028

2.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Segment by Type

2.2.1 1g/20ml

2.2.2 1.25g/25ml

2.2.3 2.5g/50ml

2.2.4 5g/100ml

2.2.5 10g/200ml

2.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type

2.3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2022)

2.3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue and Market Share by Type (2017-2022)

2.3.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Type (2017-2022)

2.4 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Segment by Application

2.4.1 Hospital

2.4.2 Clinic

2.4.3 Others

2.5 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application

2.5.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Market Share by Application (2017-2022)

2.5.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue and Market Share by Application (2017-2022)

2.5.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Application (2017-2022)

3 GLOBAL HUMAN IMMUNOGLOBULIN(PH4) FOR INTRAVENOUS INJECTION(COVID-19) BY COMPANY

3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Breakdown Data by Company

3.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Sales by Company (2020-2022)

3.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Company (2020-2022)

3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Revenue by Company (2020-2022)

3.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Company (2020-2022)

3.2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Company (2020-2022)

3.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Company

3.4 Key Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Location Distribution

3.4.2 Players Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR HUMAN IMMUNOGLOBULIN(PH4) FOR INTRAVENOUS INJECTION(COVID-19) BY GEOGRAPHIC REGION

4.1 World Historic Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Geographic Region (2017-2022)

4.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Revenue by Geographic Region

4.2 World Historic Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Country/Region (2017-2022)

4.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Sales by Country/Region (2017-2022)

4.2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Revenue by Country/Region

4.3 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth

4.4 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth

4.5 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth

4.6 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth

5 AMERICAS

5.1 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country

5.1.1 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022)

5.1.2 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022)

5.2 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type

5.3 Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region

6.1.1 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2017-2022)

6.1.2 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2017-2022)

6.2 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type

6.3 APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Country

7.1.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022)

7.1.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022)

7.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type

7.3 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Country

8.1.1 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022)

8.1.2 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022)

8.2 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type

8.3 Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

10.3 Manufacturing Process Analysis of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

10.4 Industry Chain Structure of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors

11.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Customer

12 WORLD FORECAST REVIEW FOR HUMAN IMMUNOGLOBULIN(PH4) FOR INTRAVENOUS INJECTION(COVID-19) BY GEOGRAPHIC REGION

12.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Forecast by Region

12.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecast by Region (2023-2028)

12.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecast by Type

12.7 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Boya-Bio

13.1.1 Boya-Bio Company Information

13.1.2 Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

13.1.3 Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 Boya-Bio Main Business Overview

13.1.5 Boya-Bio Latest Developments

13.2 Beijing Tiantan Biological Products

13.2.1 Beijing Tiantan Biological Products Company Information

13.2.2 Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

13.2.3 Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Beijing Tiantan Biological Products Main Business Overview

- 13.2.5 Beijing Tiantan Biological Products Latest Developments
- 13.3 Hualan Bio
 - 13.3.1 Hualan Bio Company Information
 - 13.3.2 Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
 - 13.3.3 Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.3.4 Hualan Bio Main Business Overview
 - 13.3.5 Hualan Bio Latest Developments
- 13.4 Guangdong Shuagnlin Bio-pharmacy
 - 13.4.1 Guangdong Shuagnlin Bio-pharmacy Company Information
 - 13.4.2 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
 - 13.4.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.4.4 Guangdong Shuagnlin Bio-pharmacy Main Business Overview
 - 13.4.5 Guangdong Shuagnlin Bio-pharmacy Latest Developments
- 13.5 Weiguang Biological
 - 13.5.1 Weiguang Biological Company Information
 - 13.5.2 Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
 - 13.5.3 Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.5.4 Weiguang Biological Main Business Overview
 - 13.5.5 Weiguang Biological Latest Developments
- 13.6 Sinopharm
 - 13.6.1 Sinopharm Company Information
 - 13.6.2 Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
 - 13.6.3 Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.6.4 Sinopharm Main Business Overview
 - 13.6.5 Sinopharm Latest Developments
- 13.7 Shanghai RAAS
 - 13.7.1 Shanghai RAAS Company Information
 - 13.7.2 Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
 - 13.7.3 Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Shanghai RAAS Main Business Overview

13.7.5 Shanghai RAAS Latest Developments

13.8 CTBB

13.8.1 CTBB Company Information

13.8.2 CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Product Offered

13.8.3 CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 CTBB Main Business Overview

13.8.5 CTBB Latest Developments

13.9 Nanyue Biopharming

13.9.1 Nanyue Biopharming Company Information

13.9.2 Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

13.9.3 Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Nanyue Biopharming Main Business Overview

13.9.5 Nanyue Biopharming Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & (\$ millions)
- Table 2. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & (\$ millions)
- Table 3. Major Players of 1g/20ml
- Table 4. Major Players of 1.25g/25ml
- Table 5. Major Players of 2.5g/50ml
- Table 6. Major Players of 5g/100ml
- Table 7. Major Players of 10g/200ml
- Table 8. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)
- Table 9. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2022)
- Table 10. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (\$ million)
- Table 11. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2022)
- Table 12. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Type (2017-2022) & (US\$/Unit)
- Table 13. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)
- Table 14. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2022)
- Table 15. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022)
- Table 16. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2022)
- Table 17. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Application (2017-2022) & (US\$/Unit)
- Table 18. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Company (2020-2022) & (K Units)
- Table 19. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Company (2020-2022)
- Table 20. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Company (2020-2022) (\$ Millions)

Table 21. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Company (2020-2022)

Table 22. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sale Price by Company (2020-2022) & (US\$/Unit)

Table 23. Key Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Producing Area Distribution and Sales Area

Table 24. Players Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Products Offered

Table 25. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 26. New Products and Potential Entrants

Table 27. Mergers & Acquisitions, Expansion

Table 28. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Geographic Region (2017-2022) & (K Units)

Table 29. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share Geographic Region (2017-2022)

Table 30. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Geographic Region (2017-2022) & (\$ millions)

Table 31. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Geographic Region (2017-2022)

Table 32. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country/Region (2017-2022) & (K Units)

Table 33. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country/Region (2017-2022)

Table 34. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country/Region (2017-2022) & (\$ millions)

Table 35. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country/Region (2017-2022)

Table 36. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units)

Table 37. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country (2017-2022)

Table 38. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & (\$ Millions)

Table 39. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country (2017-2022)

Table 40. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)

Table 41. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Sales Market Share by Type (2017-2022)

Table 42. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Sales by Application (2017-2022) & (K Units)

Table 43. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Sales Market Share by Application (2017-2022)

Table 44. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Sales by Region (2017-2022) & (K Units)

Table 45. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Sales Market Share by Region (2017-2022)

Table 46. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Revenue by Region (2017-2022) & (\$ Millions)

Table 47. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Revenue Market Share by Region (2017-2022)

Table 48. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Sales by Type (2017-2022) & (K Units)

Table 49. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Sales Market Share by Type (2017-2022)

Table 50. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Sales by Application (2017-2022) & (K Units)

Table 51. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Sales Market Share by Application (2017-2022)

Table 52. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Sales by Country (2017-2022) & (K Units)

Table 53. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Sales Market Share by Country (2017-2022)

Table 54. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Revenue by Country (2017-2022) & (\$ Millions)

Table 55. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Revenue Market Share by Country (2017-2022)

Table 56. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Sales by Type (2017-2022) & (K Units)

Table 57. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Sales Market Share by Type (2017-2022)

Table 58. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Sales by Application (2017-2022) & (K Units)

Table 59. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Sales Market Share by Application (2017-2022)

Table 60. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous
Injection(COVID-19) Sales by Country (2017-2022) & (K Units)

- Table 61. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country (2017-2022)
- Table 62. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & (\$ Millions)
- Table 63. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country (2017-2022)
- Table 64. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)
- Table 65. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2022)
- Table 66. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)
- Table 67. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2022)
- Table 68. Key Market Drivers & Growth Opportunities of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
- Table 69. Key Market Challenges & Risks of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
- Table 70. Key Industry Trends of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
- Table 71. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Raw Material
- Table 72. Key Suppliers of Raw Materials
- Table 73. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors List
- Table 74. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Customer List
- Table 75. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Region (2023-2028) & (K Units)
- Table 76. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Forecast by Region
- Table 77. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Region (2023-2028) & (\$ millions)
- Table 78. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share Forecast by Region (2023-2028)
- Table 79. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Country (2023-2028) & (K Units)
- Table 80. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 81. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Region (2023-2028) & (K Units)

Table 82. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 83. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Country (2023-2028) & (K Units)

Table 84. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 85. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Country (2023-2028) & (K Units)

Table 86. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 87. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Type (2023-2028) & (K Units)

Table 88. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share Forecast by Type (2023-2028)

Table 89. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Type (2023-2028) & (\$ Millions)

Table 90. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share Forecast by Type (2023-2028)

Table 91. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Application (2023-2028) & (K Units)

Table 92. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share Forecast by Application (2023-2028)

Table 93. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Application (2023-2028) & (\$ Millions)

Table 94. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share Forecast by Application (2023-2028)

Table 95. Boya-Bio Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 96. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 97. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 98. Boya-Bio Main Business

Table 99. Boya-Bio Latest Developments

Table 100. Beijing Tiantan Biological Products Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 101. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 102. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 103. Beijing Tiantan Biological Products Main Business

Table 104. Beijing Tiantan Biological Products Latest Developments

Table 105. Hualan Bio Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 106. Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 107. Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 108. Hualan Bio Main Business

Table 109. Hualan Bio Latest Developments

Table 110. Guangdong Shuagnlin Bio-pharmacy Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 111. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 112. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 113. Guangdong Shuagnlin Bio-pharmacy Main Business

Table 114. Guangdong Shuagnlin Bio-pharmacy Latest Developments

Table 115. Weiguang Biological Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 116. Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 117. Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 118. Weiguang Biological Main Business

Table 119. Weiguang Biological Latest Developments

Table 120. Sinopharm Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 121. Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 122. Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 123. Sinopharm Main Business

Table 124. Sinopharm Latest Developments

Table 125. Shanghai RAAS Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 126. Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 127. Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 128. Shanghai RAAS Main Business

Table 129. Shanghai RAAS Latest Developments

Table 130. CTBB Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 131. CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 132. CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 133. CTBB Main Business

Table 134. CTBB Latest Developments

Table 135. Nanyue Biopharming Basic Information, Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 136. Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered

Table 137. Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 138. Nanyue Biopharming Main Business

Table 139. Nanyue Biopharming Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Figure 2. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate 2017-2028 (K Units)

Figure 7. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate 2017-2028 (\$ Millions)

Figure 8. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2021 & 2028) & (\$ millions)

Figure 9. Product Picture of 1g/20ml

Figure 10. Product Picture of 1.25g/25ml

Figure 11. Product Picture of 2.5g/50ml

Figure 12. Product Picture of 5g/100ml

Figure 13. Product Picture of 10g/200ml

Figure 14. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type in 2021

Figure 15. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2022)

Figure 16. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumed in Hospital

Figure 17. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market: Hospital (2017-2022) & (K Units)

Figure 18. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumed in Clinic

Figure 19. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market: Clinic (2017-2022) & (K Units)

Figure 20. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumed in Others

Figure 21. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market: Others (2017-2022) & (K Units)

Figure 22. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2022)

Figure 23. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application in 2021

Figure 24. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market by Company in 2021 (\$ Million)

Figure 25. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Company in 2021

Figure 26. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Geographic Region (2017-2022)

Figure 27. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Geographic Region in 2021

Figure 28. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2017-2022)

Figure 29. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country/Region in 2021

Figure 30. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales 2017-2022 (K Units)

Figure 31. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue 2017-2022 (\$ Millions)

Figure 32. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales 2017-2022 (K Units)

Figure 33. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue 2017-2022 (\$ Millions)

Figure 34. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales 2017-2022 (K Units)

Figure 35. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue 2017-2022 (\$ Millions)

Figure 36. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales 2017-2022 (K Units)

Figure 37. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue 2017-2022 (\$ Millions)

Figure 38. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country in 2021

Figure 39. Americas Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country in 2021

Figure 40. United States Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 (\$ Millions)

Figure 41. Canada Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 (\$ Millions)

Figure 42. Mexico Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Revenue Growth 2017-2022 (\$ Millions)

Figure 43. Brazil Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Revenue Growth 2017-2022 (\$ Millions)

Figure 44. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Sales Market Share by Region in 2021

Figure 45. APAC Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Revenue Market Share by Regions in 2021

Figure 46. China Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Revenue Growth 2017-2022 (\$ Millions)

Figure 47. Japan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Revenue Growth 2017-2022 (\$ Millions)

Figure 48. South Korea Human Immunoglobulin(pH4) for Intravenous

Injection(COVID-19) Revenue Growth 2017-2022 (\$ Millions)

Figure 49. Southeast Asia Human Immunoglobulin(pH4) for Intravenous

Injection(COVID-19) Revenue Growth 2017-2022 (\$ Millions)

Figure 50. India Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Revenue Growth 2017-2022 (\$ Millions)

Figure 51. Australia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Revenue Growth 2017-2022 (\$ Millions)

Figure 52. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Sales Market Share by Country in 2021

Figure 53. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Revenue Market Share by Country in 2021

Figure 54. Germany Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Revenue Growth 2017-2022 (\$ Millions)

Figure 55. France Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Revenue Growth 2017-2022 (\$ Millions)

Figure 56. UK Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Revenue Growth 2017-2022 (\$ Millions)

Figure 57. Italy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Revenue Growth 2017-2022 (\$ Millions)

Figure 58. Russia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Revenue Growth 2017-2022 (\$ Millions)

Figure 59. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous
Injection(COVID-19) Sales Market Share by Country in 2021

Figure 60. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous
Injection(COVID-19) Revenue Market Share by Country in 2021

Figure 61. Egypt Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Revenue Growth 2017-2022 (\$ Millions)

Figure 62. South Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 (\$ Millions)

Figure 63. Israel Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 (\$ Millions)

Figure 64. Turkey Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 (\$ Millions)

Figure 65. GCC Country Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth 2017-2022 (\$ Millions)

Figure 66. Manufacturing Cost Structure Analysis of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) in 2021

Figure 67. Manufacturing Process Analysis of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Figure 68. Industry Chain Structure of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Figure 69. Channels of Distribution

Figure 70. Distributors Profiles

I would like to order

Product name: Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Growth 2022-2028

Product link: <https://marketpublishers.com/r/GD91A7A7453EEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD91A7A7453EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

